http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018177728-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db628fbc812ea146bb6eb24a8c0ab43a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1839 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-18 |
| filingDate | 2016-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27f785d7de3d29d35a66ff2e15a8cef9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69d911f7b0ab5ea83e1360d123f428db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3eb0ff9ce968d8575e8bfa4835005035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74112c9e3da9af8772c4ffc42261f951 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd23ca93cad2580616f9d36791327796 |
| publicationDate | 2018-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2018177728-A1 |
| titleOfInvention | Nanoparticles |
| abstract | The invention provides a (drug-containing) lipid nanoparticle with:n (i) at least one phospholipid; (ii) at least one lysolipid; and (iii) at least one phospholipid comprising a hydrophilic polymer; and (iv) at least one structural lipid of formula (I) which has the following general structure: nn n n n n n n n n n n n wherein R and R′ are long hydrocarbyl hydrophobic chains, Y is a linker element, and PHG is a polar head group described as large according to its van der Waals radius, and which is different from the phospholipid (i). n n n n n The lipid nanoparticle can release a drug (or API) from within the lipid nanoparticle as a result of focused ultrasound (FUS) applied continuously, at least twice, to a desired part of the body to induce hyperthermia (an increase in temperature). FUS is applied after the lipid nanoparticle containing the drug has been administered to the live subject, and causes controlled release of the drug at the desired site of the body. Ultrasound is then halted, and the site of interest allowed to cool. Ultrasound is then applied again. Lipid nanoparticles can be labelled (for MRI, NIRF imaging), enabling real time monitoring of the drug in the human body. Imaging information can be used to direct and guide the nature of the FUS applied to the site of interest. |
| priorityDate | 2015-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1021.